Ankara Etlik City Hospital
Ankara, Turkey (Türkiye)
NCT Number: NCT07302724
The aim of this prospective randomized controlled study was to determine whether the timing of drain removal in relation to continuous passive motion (CPM) application influences postoperative residual hematoma formation following primary total knee arthroplasty (TKA). Our primary hypothesis was that removing the drain after initiating CPM would result in less residual hematoma, as CPM-induced intra-articular fluid and blood mobilization would be evacuated through the drain before its removal, thereby reducing postoperative fluid accumulation.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Interventional
Not applicable
Ankara, Turkey (Türkiye)
This prospective, parallel-group interventional study was conducted at a single tertiary care center between June 2025 and December 2025 following approval by the institutional ethics committee. All patients provided written informed consent prior to participation.
A total of 104 consecutive patients undergoing primary unilateral total knee arthroplasty (TKA) were enrolled during the study period. During follow-up, four patients from each group were lost, leaving 96 patients available for final analysis.
Participants were allocated into two groups using a sequential alternating allocation method (2-1-2-1 sequence). Although not computer-generated, this prospective allocation approach ensured balanced group sizes throughout enrollment. Due to the nature of the intervention, allocation concealment and blinding were not applied.
All surgical procedures were performed by senior arthroplasty surgeons using a standardized medial parapatellar approach under spinal anesthesia. A uniform perioperative protocol was applied to all patients, including antibiotic prophylaxis with intravenous cefazolin and thromboembolism prophylaxis with low-molecular-weight heparin. All procedures were performed under tourniquet control. A single standard intra-articular hemovac drain of identical size and model was placed in all patients prior to wound closure.
Postoperatively, all patients underwent a standardized continuous passive motion (CPM) protocol approximately 24 hours after surgery. CPM was applied for 1 hour with a motion range of 0-90 degrees under supervision of the physiotherapy team.
The only interventional difference between study groups was the timing of drain removal in relation to CPM therapy. In the first group, the hemovac drain was removed immediately before initiation of CPM. In the second group, the drain was removed immediately after completion of the CPM session. All other perioperative care and rehabilitation protocols were identical between groups.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Hemovac drain removal performed approximately 24 hours after primary TKA, immediately before a standardized 1-hour CPM session (0-90°). All other surgical, perioperative, and rehabilitation protocols are identical across study arms.
A standardized 1-hour CPM session at 0-90° is administered approximately 24 hours after primary TKA. The hemovac drain is removed immediately after completion of the CPM session. All other surgical, perioperative, and rehabilitation protocols are identical across study arms.
Time frame: Preoperative; Postoperative Day 2; Day 14; Day 28
Residual hematoma formation assessed by knee circumference measurements at the level of the superior pole of the patella. Circumference is measured on both the operated and contralateral knees. The difference from baseline and between-group differences are evaluated.
Time frame: Postoperative Day 2; Day 14
Wound healing assessed using the Surgical Wound Aspect Score (SWAS), a clinical scoring system evaluating wound characteristics such as swelling (minimum = 0 points, maximum = 2 points), erythema (minimum = 0 points, maximum = 2 points), ecchymosis (minimum = 0 points, maximum = 2 points), blood drainage (minimum = 0 points, maximum = 2 points), and blisters (minimum = 0 points, maximum = 2 points). Finally, a score of 0 points (the best) to 10 points (the worst) was obtained by adding the results of these 5 parameters.
Time frame: Preoperative; Postoperative Day 2; Day 14; Day 28
Goniometric measurement of knee flexion and extension on the operated limb. Differences from baseline and between groups are evaluated across postoperative follow-up visits.
Time frame: Preoperative; Postoperative Day 14; Day 28
Pain intensity assessed using the Visual Analog Scale (VAS), ranging from 0 to 10, where 0 represents no pain and 10 represents the worst imaginable pain. Higher scores indicate greater pain severity.
Time frame: Preoperative; Postoperative Day 28
Functional outcome assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), ranging from 0 to 96, where higher scores indicate worse pain, stiffness, and functional limitation.
Time frame: Preoperative; Postoperative Day 28
Knee function assessed using the Lysholm Knee Score, ranging from 0 to 100, where higher scores indicate better knee function.
Time frame: Preoperative; Postoperative Day 28
Patient-reported knee function assessed using the Oxford Knee Score, ranging from 0 to 48, where higher scores indicate better knee function.
Ankara Etlik City Hospital
Other Gov
Drain Removal Before Versus After Continuous Passive Motion in Primary Total Knee Arthroplasty: Impact on Residual Hematoma in a Prospective Controlled Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07731737
Arthritis, Joint Diseases
Lahore, Pakistan
View Trial DetailsNCT07698418
Arthritis, Chronic Pain
View Trial DetailsNCT07481474
Arthritis, Joint Diseases
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT07661407
Arthritis, Joint Diseases
View Trial Details